Shares of Mast Therapeutics Inc (NASDAQ:MSTX) have earned an average recommendation of “Buy” from the six research firms that are presently covering the stock. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $1.75.
MSTX has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of Mast Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 12th. Maxim Group reiterated a “buy” rating and set a $5.00 price objective on shares of Mast Therapeutics in a report on Tuesday, July 12th. Laidlaw lowered shares of Mast Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, September 21st. Canaccord Genuity reiterated a “buy” rating and set a $3.00 price objective on shares of Mast Therapeutics in a report on Thursday, July 28th. Finally, Cowen and Company lowered shares of Mast Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, September 23rd.
A hedge fund recently raised its stake in Mast Therapeutics stock. Vanguard Group Inc. raised its stake in shares of Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned 3.11% of Mast Therapeutics worth $2,818,000 as of its most recent SEC filing.
Mast Therapeutics (NASDAQ:MSTX) opened at 0.1063 on Monday. The firm’s 50-day moving average is $0.42 and its 200 day moving average is $0.37. Mast Therapeutics has a 12-month low of $0.10 and a 12-month high of $0.71. The firm’s market cap is $22.52 million.
Mast Therapeutics (NASDAQ:MSTX) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. Equities research analysts predict that Mast Therapeutics will post ($0.20) EPS for the current year.
About Mast Therapeutics
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.